Clovis Oncology and two former executives settled SEC claims over lung cancer drug efficacy
Clovis Oncology Inc. · Oncology drug developer
The case in brief
Visible before detection
Checks that could have surfaced it, on hindsight
Governance signals
Internal efficacy data at 42% in July 2015 versus 60% claimed in public materials, per the SEC.
Can mislead when: Private companies file late, so these signals are lagging. Kubr uses them to support other flags, not to prove anything alone.
Regulatory & litigation records
FDA requests for further data on the drug, which preceded the November 2015 disclosure.
Can mislead when: Court records lag and name spellings vary. A clean record can mean the problem has not reached court yet.
Where Kubr services would have helped
Verified Snapshot
Offered in India- C8 FDA requests for further data on the drug, which preceded the November 2015 disclosure.
- C11 Internal efficacy data at 42% in July 2015 versus 60% claimed in public materials, per the SEC.
Legal diligence support
Offered in India- C8 FDA requests for further data on the drug, which preceded the November 2015 disclosure.
- C11 Internal efficacy data at 42% in July 2015 versus 60% claimed in public materials, per the SEC.
Promoter profiles
Offered in India- C8 FDA requests for further data on the drug, which preceded the November 2015 disclosure.
- C11 Internal efficacy data at 42% in July 2015 versus 60% claimed in public materials, per the SEC.
IC note
Offered in India- C8 FDA requests for further data on the drug, which preceded the November 2015 disclosure.
- C11 Internal efficacy data at 42% in July 2015 versus 60% claimed in public materials, per the SEC.
Mapped from the checks each service runs. A hindsight reading of public records, not a promise that the failure would have been found.
Same pattern
A summary of public documents. It reports what the sources say. It is not Kubr's finding and not a statement of guilt.